Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2026-02-19 00:00:00 ET · period of report 2026-02-17 · accession 0001601830-26-000019 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-19 | 2026-02-17 | RXRX | Khan Najat | CEO, Pres, Dir | F - Tax | $3.49 | -14.3K | 2.29M | -0.6% | -$49.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2026-02-17 | F | D | 14,280 | $3.49 | 2,290,383 | D | — | — |